Histone deacetylase inhibitors as a potential therapeutic agent for human cancer treatment

Targeted Oncology

Volumn 1, Issue 1, 2006, Pages 34-41

  Kouraklis, G ^a   Misiakos, E P ^a   Theocharis, S ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Advanced colorectal cancer; Gastric cancer; Gastrointestinal cancer; Hepatocellular carcinoma; Histone deacetylase inhibitors; Pancreatic cancer

Indexed keywords

EID: 33746054902     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-005-0007-9     Document Type: Review

References (89)

1. Yoshida M, Furumai R, Nishiyama M, Komatsu Y, Nishino N, Horinouchi S (2001) Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother Pharmacol 48 (Suppl 1):S20-S26
2. Dokmanovic M, Marks PA (2005) Prospects: histone deacetylase inhibitors. J Cell Biochem 96:293-304
3. Kouraklis G, Theocharis S (2002) Histone deacetylase inhibitors and anticancer therapy. Curr Med Chem-ACA 2:477-484
4. Fang JY (2005) Histone deacetylase inhibitors, anti-cancerous mechanism and therapy for gastrointestinal cancers. J Gastroenterol Hepatol 20:988-994
5. Timmerman S, Lehrmann H, Popesskaya A, Harel-Bellan A (2001) Histone acetylation and disease. Cell Mol Life Sci 58:728-736
6. Miller TA, Witter DJ, Belvedere S (2003) Histone deacetylase inhibitors. J Med Chem 46:5097-5116
7. Johnstone RW, Licht JD (2003) Histone deacetylase inhibitors in cancer therapy:Is transcription the primary target? Cancer Cell 4:13-18
8. Lehrmann H, Pritchard LL, Harel-Bellan A (2002) Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation. Adv Cancer Res 86:41-65
9. Sengupta N, Seto E (2004) Regulation of histone deacetylase activities. J Cell Biochem 93:57-67
10. Chen JS, Faller DV, Spanjaard RA (2003) Short-chain fatty acid inhibitors of histone deacetylases:promising anticancer therapeutics? Curr Cancer Drug Targets 3:219-236
11. Bannister AJ, Kouzarides T (1996) The GBP co-activator is a histone acetyltransferase. Nature 384:641-643
12. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS (2001) Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276:36734-36741
13. Rhodes D. Chromatin structure (1997) The nucleosome core all wrapped up. Nature 389:231-233
14. Lindemann RK, Gabrielli B, Johnstone RW (2004) Histone-deacetylase inhibitors for the treatment of cancer. Cell Cycle 3:779-788
15. Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC (2005) Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 45:495-528
16. Taunton J, Hassig CA, Scheiber SL (1996) A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3.p. Science 272:408-411
17. Grozinger CM, Hassig CA, Schreiber SL (1999) Three proteins define a class of human histone deacetylases related to yeast Hda1.p. Proc Natl Acad Sci USA 96:4868-4873
18. Fischle W, Emiliani S, Hendzel MJ, Nagase T, Nomura N, Voelter W, Verdin E (1999) A new family of human histone deacetylases related to Saccharomyces cerevisiae HDA1 p. J Biol Chem 274:11713-11720
19. waf1/cip1 promoter activity induced by histone deacetylase inhibitor. J Biol Chem 275:1371-1376
20. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Hideshima T, Akiyama M, Chauhan D, Munshi N, Gu X, Bailey C, Joseph M, Libermann TA, Richon VM, Marks PA, Anderson KC (2004) Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA 101: 540-545
21. Siavoshian S, Segain JP, Kornprobst M, Bonnet C, Cherbut C, Galmiche JP, Blottiere HM (2000) Butarate and Trichostatin A effects on the proliferation/differentiation of human intestinal epithelial cells: induction of cyclin D3 and p21 expression. Gut 46:507-514
22. Rosato RR, Almenara JA, Grant S (2003) The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res 63:3637-3645
23. Furumai R, Komatsu Y, Nishino N, Khochbin S, Yoshida M, Horinouchi S (2001) Potent histone deacetylase inhibitors built from Trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc Natl Acad Sci USA 98:87-92
24. Meinke PT, Colletti SL, Doss G, Myers RW, Gurnett AM, Dulski PM, Darkin-Rattray SJ, Allocco JJ, Galsuska S, Schmatz DM, Wyvratt MJ, Fisher MH (2000) Synthesis of apicidin-derived quinolone derivatives: parasite-selective histone deacetylase inhibitors and antiproliferative agents. J Med Chem 43:4919-4922
25. Richon VM, Emiliani S, Verdin E, Webb Y, Breslow R, Rifkind RA, Marks PA (1998) A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA 95:3003-3007
26. Kim YB, Lee KH, Sugita K, Yoshida M, Horinouchi S (1999) Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene 18:2461-2470
27. Keen JC, Yan L, Mack KM, Petitt C, Smith D, Sharma D, Davidson NE (2003). A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2′-deoxycytidine. Breast Cancer Res Treat 81:177-186
28. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS (2001) Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276:36734-36741
29. Kwon HJ, Owa T, Hassig CA, Shimada J, Schreiber SL (1998) Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase. Proc Natl Acad Sci 95:3356-3361
30. Butler LM, Webb Y, Agus DB, Higgins B, Tolentino TR, Kutko MC, LaQuaglia MP, Drobnjak M, Cordon-Cardo C, Scher HI, Breslow R, Richon VM, Rifkind RA, Marks PA (2001) Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. Clin Cancer Res 7:962-970
31. Gregory PD, Wagner K, Horz W (2001) Histone acetylation and chromatin remodeling. Exp Cell Res 265:195-202
32. Roth SY, Denu JM, Allis CD (2001) Histone acetyltransferases. Ann Rev Biochem 70:81-120
33. L, c-Jun, and p21 CIP1, but independent to p53. Oncogene 18:7016-7025
34. Park JH, Jung Y, Kim TY, Kim SG, Jong HS, Lee JW, Kim DK, Lee JS, Kim NK, Kim TY, Bang YJ (2004) Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation. Clin Cancer Res 10:5271-5281
35. Garber K (2004) Purchase of Aton spotlights HDAC inhibitors. Nat Biotechnol 22:364-365
36. Richon VM, O'Brien JP (2002) Histone deacetylase inhibitors. Clin Cancer Research 8:662-664
37. Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG, Davidsen SK (2003) Mol Cancer Ther 2:151-163
38. Peart MJ, Smyth GK, van Laar RK, Bowtell DD, Richon VM, Marks PA, Holloway AJ, Johnstone RW (2005) Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci USA 102:3697-3702
39. Theocharis S, Margeli A, Kouraklis G (2003) Peroxisome proliferator activated receptor-gamma ligands as potent antineoplastic agents. Curr Med Chem-ACA 3:239-251
40. Warrener R, Beamish H, Burgess A, Waterhouse NJ, Giles N, Fairlie D, Gabrielli B (2003) Tumor cell-selective cytotoxicity by targeting cell cycle checkpoints. FASEB J 17:1550-1552
41. Qiu L, Burgess A, Fairlie DP, Leonard H, Parsons PG, Gabrielli BG (2000) Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. Mol Biol Cell 11:2069-2083
42. Fang JY, Lu YY (2002) Effects of histone acetylation and DNA methylation on p21 (WAF1) regulation. World J Gastroenterol 8:400-405
43. Vigushin DM, Coombes RC (2002) Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs 13:1-13
44. Henderson C, Mizzau M, Paroni R, Schneider C, Brancolini C (2003) Role of caspaces, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors Trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA). J Biol Chem 278:12579-12589
45. Shin HJ, Baek KH, Jeon AH, Kim SJ, Jang KL, Sung YC, Kim CM, Lee CW (2003) Inhibition of histone deacetylase activity increases chromosomal instability by the aberrant regulation of mitotic checkpoint activation. Oncogene 22:3853-3858
46. Han JW, Ahn SH, Park SH, Wang SY, Bae GU, Seo DW, Kwon HK, Hong S, Lee HY, Lee YW, Lee HW (2000) Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin. Cancer Res 60:6068-6074
47. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB (1999) Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21:103-107
48. Peart M, Tainton KM, Ruelfi AA, Dear AE, Sedelies KA, O'Reilly LA, Waterhouse NJ, Trapani JA, Johnstone RW (2003) Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res 63:4460-4471
49. Johnstone RW, Ruefli AA, Lowe SW (2002) Apoptosis: a link between cancer genetics and chemotherapy. Cell 108:153-164
50. Johnstone RW (2002) Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 1:287-299
51. Ruefli AA, Ausserlechner MJ, Bernhard D, Sutton VR, Tainton KM, Kofler R, Smyth MJ, Johnstone RW (2001) The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA 98:10833-10838
52. Sonnemann J, Gange J, Kumar KS, Muller C, Bader P, Beck JF (2005) Histone deacetylase inhibitors interact synergistically with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to induce apoptosis in carcinoma cell lines. Invest New Drugs 23:99-109
53. Kim YB, Ki SW, Yoshida M, Horinouchi S (2000) Mechanism of cell cycle arrest caused by histone deacetylase inhibitors inhuman carcinoma cells. J Antibiot 53:1191-1200
54. Mello JA, Almouzni G (2001) The ins and outs of nucleosome assembly. Curr Opin Genet Dev 11:136-141
55. Klionsky DJ, Emr SD (2000) Autophagy as a regulatory pathway of cellular degradation. Science 290:1717-1721
56. Klionsky DJ (2004) Cell biology: regulated self-cannibalism. Nature 431:31-32
57. Gozuacik D, Kimchi A (2004) Autophagy as a cell death and tumor suppressor mechanism. Oncogene 23:2891-2896
58. Wang CW, Klionsky DJ (2003) The molecular mechanism of autophagy. Mol Med 9:65-76
59. Mills KR, Reginato M, Debnath J, Queenan B, Brugge JS (2004) Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is required for induction of autophagy during lumen formation in vitro. Proc Natl Acad Sci USA 101:3438-3443
60. Mie Lee Y, Kim SH, Kim HS, Jin Son M, Nakajima H, Jeong Kwon H, Kim KW (2003) Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1 alpha activity. Biochem Biophys Res Commun 300:241-246
61. Kim MS, Kwon HJ, Lee YM, Baek JH, Jang JE, Lee SW, Moon EJ, Kim HS, Lee SK, Chung HY, Kim CW, Kim KW (2001) Deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 7:437-443
62. Kelly WK, Marks AP (2005) Drug insight:Histone deacetylase inhibitors development of the new targeted anticancer agent suberolyanilide hydroxyamic acid. Nat Clin Prac 2:1-8
63. Ungerstedt JS, Sowa Y, Xu WS, Shao Y, Dokmanovic M, Perez G, Ngo L, Holmgren A, Jiang X, Marks PA (2005) Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA 102:673-678
64. WAF1 expression in human colon cancer lines. World J Gastroenterol 10:2643-2646
65. Hinnebusch BF, Meng S, Wu JT, Archer SY, Hodin RA (2002) The effects of short-chain fatty acids on human colon cancer cell phenotype are associated with histone hyperacetylation. J Nutr 132:1012-1017
66. Kraker AJ, Mizzen CA, Hartl BG, Miin J, Allis CD, Meriman RL (2003) Modulation of histone acetylation by [4-(acetylamino)-N-(2-amino-phenyl) benzamide] in HCT-8 colon carcinoma. Mol Cancer Ther 2:401-408
67. Zhang Y, Adachi M, Zhao X, Kawamura R, Imai K (2004) Histone deacetylase inhibitors FK228, N-(2-aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbomyl)amino- methyl]benzamide and m-carboxycinnamic acid bis-hydroxamide augment radiation-induced cell death in gastrointestinal adenocarcinoma cells. Int J Cancer 110:301-308
68. Zaugg K, Rocha S, Resch H, Hegyi I, Oehler C, Glanzmann C, Fabbro D, Bodis S, Pruschy M (2001) Differential p53-dependent mechanism of radiosensitization in vitro and in vivo by the protein kinase C-specific inhibitor PKC412. Cancer Res 61:732-738
69. Lawrence TS, Davis MA, Hough A, Rehemtulla A (2001) The role of apoptosis in 2′, 2′-difluoro-2′- deoxycytidine (gemcitabine)-mediated radiosensitization. Clin Cancer Res 7:314-319
70. Wolffe AP, Hansen JC (2001) Nuclear visions, functional flexibility form structural instability. Cell 104:631-634
71. Johnstone RW (2002) Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 1:287-299
72. Coradini D, Speranza A (2005) Histone deacetylase inhibitors for the treatment of hepatocellular carcinoma. Acta Pharmacol Sin 26:1025-1033
73. Herold C, Ganslmayer M, Ocker M, Hermann M, Geerts A, Hahn EG, Schuppan D (2002) The histone-deacetylase inhibitor Trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells. J Hepatol 36:233-240
74. Svechnikova I, Gray SG, Kundrotiene J, Ponthan F, Kogner P, Ekstrom TJ (2003) Apoptosis and tumor remission in liver tumor xenografts by 4-phenylbutyrate. Int J Oncol 22:579-588
75. Armeanu S, Pathil A, Venturelli S, Mascagni P, Weiss TS, Gottlicher M, Gregor M, Lauer UM, Bitzer M (2005) Apoptosis on hepatoma cells but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357. J Hepatol 42:210-217
76. Choi HS, Lee JH, Park JG, Lee YI (2002) Trichostatin A, a histone deacetylase inhibitor, activates the IGFBP-3 promoter by upregulating Sp1 activity in hepatoma cells:alteration of the Sp1/Sp3/HDAC1 multiprotein complex. Biochem Biophys Res Commun 296:1005-1012
77. Garcia-Morales P, Gomez-Martinez, Carrato A, Martinez-Lacaci I, Barbera VM, Soto JL, Carrasco-Garcia E, Menendez-Gutierrez MP, Castro-Galache MD, Ferragut JA, Saceda M (2005) Histone deacetylase inhibitors induced caspase-independent apoptosis in human pancreatic adenocarcinoma cell lines. Mol Cancer Ther 4:1222-1230
78. Donadelli M, Constanzo C, Faggioli L, Scupoli MT, Moore PS, Bassi C, Scarpa A, Palmieri M (2003) Trichostatin A, an inhibitor of histone deacetylases, strongly suppresses growth of pancreatic adenocarcinoma cells. Mol Carcinog 38:59-69
79. Sato N, Ohta T, Kitagawa H, Kayahara M, Ninomiya I, Fushida S, Fujimura T, Nishimura G, Shimizu K, Miwa K (2004) FR901228, a novel histone deacetylase inhibitor, induces cell-cycle arrest and subsequent apoptosis in refractory human pancreatic cancer cells. Int J Oncol 24:679-685
80. Correa P (1992). Human gastric carcinogenesis: a multi-step and multi-factorial process: first American Cancer Society award lecture on cancer epidemiology and prevention. Cancer Res 52:6735-6740
81. Kim JH, Choi YK, Kwon HJ, Yang HK, Choi JH, Kim DY (2004) Downregulation of gelsolin and retinoic acid receptor beta expression in gastric cancer tissues through histone deacetylase 1. J Gastroenterol Hepatol 19:218-224
82. Hase K, Murakami M, Iimura M, Cole SP, Horibe Y, Ohtake T, Obonyo M, Gallo RL, Eckmann L, Kagnoff MF (2003) Expression of LL-37 by human gastric epithelial cells as potential host defense mechanism against Helicobacter pylori. Gastroenterology 125:1613-1625
83. Bals R, Wilson JM (2003) Cathelicidins - a family of multifunctional antimicrobial peptides. Cell Mol Life Sci 60:711-720
84. Schauber J, Iffland K, Frisch S, Kudlich T, Schmausser B, Eck M, Menzel T, Gostner A, Luhrs H, Scheppach W (2004) Histone-deacetylase inhibitors induce the cathelicidin LL-37 in gastrointestinal cells. Mol Immunol 41:847-854
85. Villar-Garea A, Esteller M (2004) Histone deacetylase inhibitors: understanding a new wave of anticancer agents. Int J Cancer 112:171-178
86. Kramer OH, Gottlicher M, Heinzel T (2001) Histone deacetylase as a therapeutic agent. Trends Endocrinol Metab 12:294-300
87. McIntyne A, Gibson PR, Young GP (1993) Butyrate production from dietary fibers and protection against large bowel cancer in a rat model. Gut 34:386-391
88. Saito A, Yamashita T, Mariko Y, Nosaka Y, Tsuchiya K, Ando T, Suzuki T, Tsuruo T, Nakanishi O (1999) A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acd Sci USA 96:4592-4597
89. Shinji C, Nakamura T, Maeda S, Yoshida M, Hashimoto Y, Miyachi H (2005) Design and synthesis of phthalimide-type histone deacetylase inhibitors. Bioorg Med Chem Lett 15:4427-4431